Objective:To evaluate the therapeutic efficacy and toxicity of docetaxel combined with low-dose cisplatin as alternative chemotherapy for advanced non-small-cell lung cancer.Methods:Sixty-two patients with non-small-cell lung cancer received docetaxel combined with cisplatin chemotherapy,docetaxel 75mg/m2 infusion once per week for three weeks,cisplatin 25mg/m2 infusion on d1-3 for three weeks,after two consecutive therapy course,each for 3 weeks,evaluation of short term efficacy and side effects were carried out.Results:All patients received more than 2 courses chemotherapy and the overall response rate was 46.78%,the median survival rate was 9.6 months.The main toxic reactions included alopecia and myelosuppression,the rates were 88.71% and 85.48%,grade Ⅲ-Ⅳ reactive rates were 14.52% and 8.06%.Conclusion:Combined chemotherapy of docetaxel and low dose cisplatin for non-small-cell lung cancer is effective and well tolerated.